Page 1 of 1

QUESTION 46 Which of the following is true for "non-progressors"? O a. Maintain a CD4 count of greater than or equal to

Posted: Tue May 17, 2022 1:59 pm
by answerhappygod
Question 46 Which Of The Following Is True For Non Progressors O A Maintain A Cd4 Count Of Greater Than Or Equal To 1
Question 46 Which Of The Following Is True For Non Progressors O A Maintain A Cd4 Count Of Greater Than Or Equal To 1 (67.34 KiB) Viewed 112 times
Question 46 Which Of The Following Is True For Non Progressors O A Maintain A Cd4 Count Of Greater Than Or Equal To 2
Question 46 Which Of The Following Is True For Non Progressors O A Maintain A Cd4 Count Of Greater Than Or Equal To 2 (63.25 KiB) Viewed 112 times
Question 46 Which Of The Following Is True For Non Progressors O A Maintain A Cd4 Count Of Greater Than Or Equal To 3
Question 46 Which Of The Following Is True For Non Progressors O A Maintain A Cd4 Count Of Greater Than Or Equal To 3 (53.76 KiB) Viewed 112 times
QUESTION 46 Which of the following is true for "non-progressors"? O a. Maintain a CD4 count of greater than or equal to 450 cells/ul. O b. Have a viral load of <100 HIV RNA copies/mL. O c. Have a viral load of <5000 HIV RNA copies /mL O d. Both a and c. QUESTION 47 The greatest risk of HIV infection occurs: O a. During the Acute phase shortly after infection b. Within the first few months after infection. O c. When the CD4+ T cell count drops below 200 cells/uL (AIDS Stage). O d. All of the above

QUESTION 48 Which of the following is a biological marker used to track HIV progression? O a. p24 antigen levels O b.p24 antibody levels O c. both a and b QUESTION 49 What is the average length of the Asymptomatic Stage (without drugs)? O a. 6 months O b.5 years O c. 8 years d. 11 years

QUESTION 50 The T cell co-receptor favored by HIV in the late phase of infection is: O a. CXCR4 O b.CCR5 O c. CD4 O d.CD8 QUESTION 51 30% of HIV-infected individuals are co-infected with this virus that is associated with faster progression to AIDS. O a. HCV O b.HBV Ос. HPV d. CMV